List of Excipients in Branded Drug ERVEBO

Excipient Strategy and Commercial Opportunities for ERVEBO

Last updated: March 3, 2026

What excipients are used in ERVEBO and what role do they play?

ERVEBO (Zaire ebolavirus vaccine, live zEbov, vaccine), developed by Johnson & Johnson, includes specific excipients designed to stabilize the vaccine and enhance its shelf life.

Key excipients in ERVEBO:

• Disodium phosphate dihydrate and potassium dihydrogen phosphate: buffer agents maintaining pH stability.
• Sucrose: stabilizes the viral vector, preventing degradation.
• Tris (hydroxymethyl) aminomethane: buffer component.
• Water for injection: solvent medium.

These excipients maintain the integrity of the vaccine during storage and transport, critical given the vaccine's requirement for cold chain management.

How do excipient choices influence ERVEBO’s stability and shelf life?

Excipients directly impact the vaccine’s stability profile:

• Sucrose functions as a lyoprotectant, preserving viral viability during freeze-thaw cycles.
• Buffer agents ensure pH remains within the optimal range (approximately 7.0 to 7.4), prolonging the vaccine’s efficacy.
• The formulation allows for a shelf life of up to 24 months at 2-8°C, aligning with WHO recommendations for vaccines used in challenging logistics environments.

What are the commercial implications of excipient strategies in ERVEBO?

Cost considerations

• The excipients used are relatively low-cost; however, their formulation stability reduces wastage, especially in regions with limited cold chain infrastructure.
• Manufacturing cost efficiencies can be achieved through optimized excipient ratios, reducing overall production expenses.

Regulatory pathways and compatibility

• Excipient selection adheres to regulatory standards set by the FDA and EMA.
• Compatibility with existing cold chain logistics simplifies approval processes and enhances distribution.

Market expansion opportunities

• Formulation robustness allows ERVEBO to be stored in a wider range of environments, supporting deployment in remote or resource-limited settings.
• Potential development of lyophilized (freeze-dried) formulations with alternative stabilizers could extend shelf life and facilitate shipment, opening markets with logistical constraints.

Future pipeline innovations

• Incorporating novel excipients such as trehalose or polysaccharides could enhance stability, enabling temperature-independent storage.
• Investments in excipient research support formulation adaptations for different delivery platforms or combination vaccines, broadening commercial scope.

Are there opportunities for excipient innovation to expand ERVEBO’s market?

Yes. Developing formulations with alternative stabilizers or lyophilized forms can:

• Reduce cold chain dependence.
• Enhance shelf stability.
• Lower overall cost points for global distribution.

Potential research includes:

• Use of amino acids like glycine for stabilization.
• Replacement of traditional buffers with advanced systems to improve thermal stability.
• Formulation of single-dose, pre-filled syringes with embedded stabilizers for ease of administration.

What are the supply chain considerations related to excipient strategy?

Supply chain stability depends on:

• Reliable sourcing of excipients in global markets.
• Manufacturing scalability aligned with demand surges, such as during outbreaks.
• Storage conditions for excipients to prevent degradation before formulation.

Johnson & Johnson’s established supply infrastructure supports the consistent availability of excipients, but ongoing monitoring for raw material shortages remains necessary, especially if novel excipients are adopted.

How might excipient strategy evolve for future Ebola vaccines or COVID-19 vaccine adaptation?

• Use of excipients enabling room-temperature storage could become standard to facilitate broader distribution.
• Adoption of microcrystalline or amorphous stabilizers may extend shelf life.
• Formulation innovations targeting thermostability could reduce dependence on cold chain, unlocking new markets.

Key Takeaways

• ERVEBO’s excipient formulation prioritizes stability under cold chain conditions, with low-cost components facilitating distribution.
• Opportunities exist for excipient innovations to extend shelf life and improve logistical deployment.
• Regulatory compliance and supply chain reliability remain critical factors influencing formulation strategies.
• Formulation advancements can expand ERVEBO’s reach in resource-limited regions and prepare for future vaccine development.

FAQs

1. What are the main excipients in ERVEBO?
   Sucrose, buffer agents (disodium phosphate, potassium dihydrogen phosphate, Tris), and water for injection.

2. Can ERVEBO be stored at room temperature?
   Typically no. It requires storage at 2-8°C. Formulation innovations may enable room-temperature stability in the future.

3. Are there potential excipient improvements for ERVEBO?
   Yes. Use of stabilizers like trehalose or lyophilized formulations could enhance stability and logistics flexibility.

4. How do excipients influence vaccine cost and distribution?
   They contribute minimally to cost but improve stability and shelf life, reducing wastage and facilitating wider distribution.

5. What challenges exist in sourcing excipients for ERVEBO?
   Ensuring consistent supply, especially for novel stabilizers, and maintaining excipient purity and quality over large-scale production.

---

References

[1] World Health Organization. (2020). Prequalification Programme, ERVEBO vaccine product dossier.
[2] Johnson & Johnson. (2022). Product Information for ERVEBO.
[3] Food and Drug Administration. (2020). Summary of ERVEBO (Zaire ebolavirus vaccine, live, attenuated).
[4] EMA. (2021). Summary of product characteristics for ERVEBO.